WAL 801 CL Dry Syrup in Paediatric Atopic Dermatitis Patients

Dermatitis, Atopic Clinical Trial

Official title:

Phase III Double-Blind Comparative Study of WAL 801 CL Dry Syrup in Paediatric Atopic Dermatitis Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02182557
• Other study ID #: 262.259
• Status: Completed
• Phase: Phase 3
• First received: July 2, 2014
• Last updated: July 11, 2014
• Start date: June 2001

Study information

• Verified date: July 2014
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Ministry of Health, Labor and Welfare
• Study type: Interventional

Clinical Trial Summary

Study to investigate the safety and efficacy of WAL 801 CL Dry Syrup on pruritus associated with paediatric atopic dermatitis in comparison with that of Ketotifen Fumarate Dry Syrup and to confirm the appropriateness of dosage of WAL801 Dry Syrup.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 162
• Est. primary completion date: January 2002
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A to 15 Years

Eligibility

Inclusion Criteria:

For inclusion in this study, patients must be pediatric atopic dermatitis patients that meet the following criteria and thus be appropriate for observation of pruritus. Diagnosis of atopic dermatitis was conducted in accordance with the "Definition and Diagnostic Criteria of Atopic Dermatitis" issued by the Japanese Dermatological Association.

• 15 years of age or younger

• Body weight of 14 kg or more

• Outpatients

• One week or longer has passed since the patient started to use an external steroid preparation at "Strong" or lower grade, or stopped using any external steroid preparation, at the time of obtainment of consent from the patient

• Pruritus with "2" or higher grade, immediately before initial administration

Exclusion Criteria:

• Use of sustained release adrenocorticotropic hormone (Kenacort® A, Depo-medrol®, etc.), oral preparation of methotrexate, or oral preparation of ciclosporin, within 4 weeks before initial administration of the investigational product

• Oral intake, inhalation and injection of any steroid within 2 weeks before initial administration of the investigational product

• Use of any external steroid preparation at "Very Strong" or higher grade in any sites other than the face or scalp within 2 weeks before initial administration of the investigational product

• Undergoing phototherapy

• Undergoing specific desensitization therapy or modulation therapy

• Past history of contact dermatitis caused by external steroid preparation

• Possibility of exacerbation by an external steroid preparation of infectious skin disease caused by bacteria, fungi, or virus

• Present and past history of convulsive disorder, such as epilepsy (convulsion threshold values may be lowered by the reference drug, Ketotifen Fumarate)

• Clinically significant hepatic, renal, or cardiac disease or other complications:

therefore, judgement that the patient is ineligible for inclusion in this study (Please note that patients must be excluded from the study if the patients fell under Grade 2 or more, in the MHW (Ministry of health and welfare) Adverse Reaction Severity Classification Criteria.)

• Past history of allergy to any drug

• Participation in any other clinical study, or history of participation in any other clinical study within 6 months before the date when the patient gave consent to participate in this study

• Judgement by the Principal Investigator or Investigator that the patient is ineligible for inclusion in this study

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Dermatitis
• Dermatitis, Atopic
• Eczema

Intervention

Drug:
• WAL 801 CL Dry Syrup

• Ketotifen Fumarate Dry Syrup

• WAL 801 CL Dry Syrup placebo

• Ketotifen Fumarate Dry Syrup placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Degree of pruritus		at week 4	No
Secondary	Degree of pruritus		at week 2	No
Secondary	Degree of rash		at weeks 2 and 4	No
Secondary	Pruritus score obtained through the itching questionnaire		at weeks 2 and 4	No
Secondary	Impression on pruritus of the patient or the parent		at week 4	No
Secondary	Occurrence of adverse events		up to 4 weeks	No
Secondary	Number of patients with abnormal changes from baseline in laboratory measurements (hematological tests, blood biochemical tests, and urinalysis)		Baseline and week 4	No

External Links

•   Link